Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator AwardDr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research’s esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare ConferenceSEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference.
Nautilus Biotechnology Reports Third Quarter 2024 Financial ResultsSEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024.
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024.
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing OfficerIndustry veteran brings multidisciplinary expertise leading Mass Spectrometry division at Agilent Technologies to a company building a platform to power next-generation proteomics
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceSEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.
Nautilus Biotechnology Reports Second Quarter 2024 Financial ResultsSEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024.
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024.
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceSEATTLE, May 23, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference.
Nautilus Biotechnology Reports First Quarter 2024 Financial ResultsSEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsSEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare ConferenceSEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference.
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024.
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics AwardSociety award recognizes Dr. Mallick’s decades of innovative leadership and science advancing the field of computational proteomics
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell DevelopmentFormer Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome
Nautilus Biotechnology Reports Third Quarter 2023 Financial ResultsSEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023.
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023.
Nautilus Biotechnology to Participate in Upcoming September Investor ConferencesSEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:
Nautilus Biotechnology to Participate in Upcoming August Investor ConferencesSEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:
Nautilus Biotechnology Reports Second Quarter 2023 Financial ResultsSEATTLE, Wash., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2023.
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter before market open on Wednesday, August 2, 2023.
Nautilus Biotechnology to Participate in Upcoming June Investor ConferencesSEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:
Nautilus Biotechnology Reports First Quarter 2023 Financial ResultsSEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2023.
Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023SEATTLE, April 18, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter before market open on Tuesday, May 2, 2023.
Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual ConferenceSEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference.
Nautilus Biotechnology Announces “First Access Challenge” WinnersResearchers from Buck Institute for Research on Aging, Brigham Young University and University of Southern California awarded early access to Nautilus’ single-molecule protein analysis platform
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsSEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care ConferenceSEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming 43rd Annual Cowen Health Care Conference.
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2022 before market open on Thursday, February 23, 2023.
Nautilus Biotechnology Expands to San DiegoProteomics company opens new office in Southern California to facilitate ongoing research and team growth aimed at unlocking the potential of the proteome
Nautilus Biotechnology Launches “First Access Challenge”Open competition allows researchers to be among the first to access potentially groundbreaking proteomic data through the testing of twelve samples on Nautilus’ single-molecule protein analysis platform
Nautilus Biotechnology Reports Third Quarter 2022 Financial ResultsSEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022.
Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter 2022 before market open on Tuesday, November 1, 2022.
